The System Anti-Infective P&T Subcommittee has approved a formulary restriction for ivermectin (Stromectol). As of Sept. 21, 2021, ivermectin is RESTRICTED to FDA-approved indications only.
The System Anti-Infective P&T Subcommittee has approved a formulary restriction for ivermectin (Stromectol). As of Sept. 21, 2021, ivermectin is RESTRICTED to FDA-approved indications only.
This restriction was approved by System P&T in an effort to reduce ivermectin prescribing for COVID-19 treatment and/or prophylaxis. Ivermectin has failed to demonstrate benefit in COVID-19, although misinformation continues to drive patient requests for use. The CDC and FDA have warned against use in COVID-19, citing an increase in ivermectin-associated adverse event reports over the past few months. Organizations such as NIH, IDSA, and WHO currently recommend against the use of ivermectin for COVID-19 outside of clinical trials.
This restriction impacts all hospitals and UNC clinics. Inpatient and outpatient providers are required to follow restrictions and avoid use for COVID-19 treatment/prophylaxis.
Please reach out to David Weber and/or Erin Maxwell with questions.